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Objectives: HIV-1 subtype C might have a greater propensity to develop K65R mutations in patients with viro-
logical failure compared with other subtypes. However, the strong association between viral subtype and con-
founding factors such as exposure groups and ethnicity affects the calculation of this propensity. We exploited
the diversity of viral subtypes within the UK to undertake a direct comparative analysis.
Patients andmethods: We analysed only sequences with major IAS-defined mutations from patients with viro-
logical failure. Prevalence of K65R was related to subtype and exposure to the NRTIs that primarily select for this
mutation (tenofovir, abacavir, didanosine and stavudine). A multivariate logistic regression model quantified the
effect of subtype on the prevalence of K65R, adjusting for previous and current exposure to all four specified
drugs.
Results: Subtype B patients (n"3410) were mostly MSM (78%) and those with subtype C (n"810) were mostly
heterosexual (82%). K65R was detected in 7.8% of subtype B patients compared with 14.2% of subtype C pa-
tients. The subtype difference in K65R prevalence was observed irrespective of NRTI exposure and K65R was fre-
quently selected by abacavir, didanosine and stavudine in patients with no previous exposure to tenofovir.
Multivariate logistic regression confirmed that K65R was significantly more common in subtype C viruses
(adjusted OR"2.02, 95% CI"1.55–2.62, P,0.001).
Conclusions: Patients with subtype C HIV-1 have approximately double the frequency of K65R in our database
compared with other subtypes. The exact clinical implications of this finding need to be further elucidated.
Introduction
K65R is the signature mutation associated with tenofovir resist-
ance1 and also confers significant cross-resistance to abacavir, di-
danosine and stavudine.2–4 For reasons that are not entirely clear,
it seems that the genetic barrier to K65R development is not as low
as with some other NRTIs and NNRTIs. It is well established that
the M184V mutation develops quickly in patients failing on emtrici-
tabine/lamivudine, which is not the case for K65R even though it re-
quires only a single nucleotide A–G change at reverse transcriptase
(RT) codon 65 to cause the lysine to arginine amino acid change.
This A–G point mutation happens regardless of the viral subtype.
The low prevalence of K65R seen in clinical trials and in various
resistance databases would support the premise that K65R does
not develop that easily in settings where virological failure is well
controlled. Worryingly a recent worldwide multicentre retrospect-
ive cohort study in patients with treatment failure on tenofovir and
NNRTI-based regimens found the K65R prevalence to range from
below 20% in Europe and North America to 50% in sub-Saharan
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Africa.5 The wide variation in K65R prevalence is most likely ex-
plained by different standards of care, with slower switching after
virological failure allowing for greater accumulation of drug resist-
ance to all classes. However, the influence of subtype, which is
mostly inextricably linked to demographics, cannot be excluded.
Subtype C viruses are more likely to develop K65R mutations in
patients with virological failure than other HIV-1 subtypes. In vitro
experiments show that the mutation is more easily selected during
serial passage than with other subtypes.6 There is also strong
mechanistic evidence for the facilitated development of the K65R
mutation based on the viral template in the codon 64, 65 and 66
RT region found in subtype C.7 Some retrospective cohort studies
that have looked at factors associated with the emergence of
K65R have identified subtype C to be a predictive factor.8,9
However, additional data to support the reported subtype-de-
pendent selection of K65R is needed especially if it can clearly dis-
tinguish between the influence of subtype, exposure groups and
ethnicity.
The UK national database is well placed to differentiate be-
tween these factors as it collects diverse HIV resistance and sub-
type data typical of the UK HIV epidemic and the aim of this study
was to undertake a direct comparative analysis and to determine
whether K65R is detected more frequently in subtype C viruses at
virological failure.
These questions are important given the global distribution of
subtype C and the widespread use of tenofovir in first-line
combinations.10
Patients and methods
The UK HIV Drug Resistance Database (UKHDRD) has collated the vast ma-
jority of genotypic resistance tests conducted in the UK since the assay was
first introduced as part of routine clinical care. Partial pol sequences (encod-
ing the protease gene and at least codons 34–234 of RT) generated by
Sanger sequencing are transferred electronically from participating labora-
tories, which use a variety of commercial or in-house assays. A quality as-
surance programme, in which all laboratories participate, is carried out
annually. Tests in the present analysis were conducted between 1996 and
2012. As the absence of any major International AIDS Society (IAS)–USA
2013 list11 mutation in a resistance test implies that therapeutic failure was
due to lack of drug pressure, such tests were considered uninformative and
not included in the analysis.
Patients were considered eligible for the analysis if the following criteria
were met: (i) clinical care was received at a centre participating in the UK
Collaborative HIV Cohort (UK CHIC) Study (detailed clinical and demo-
graphic data, including a complete ART history, are provided by these
centres to which resistance test results are regularly linked); (ii) at least one
(non-WT) resistance test had been conducted after ART initiation; (iii) K65R
had not been detected in any tests conducted prior to ART initiation; and
(iv) viral subtype could be assigned based on the nucleotide sequence from
a resistance test (see section below).
If the K65R mutation was ever detected (including as a mixture with
WT) in an individual patient, the complete ART history until the first sample
with this mutation was considered; if K65R was never detected, the pa-
tient’s complete ART history until the last sample was considered. ART his-
tory was summarized in terms of indicator variables reflecting current and
previous (not current) exposure to specific NRTIs, and current and past ex-
posure to the NNRTI and PI classes in general. Exposure was defined as tak-
ing a drug for a minimum of 30 days cumulatively, and current exposure
was defined as taking the drug at the time of the resistance test or having
stopped within the previous 14 days. The specific NRTIs were chosen a priori
on the basis that they were known to select for K65R (tenofovir, abacavir, di-
danosine and stavudine)1–4,12,13 or to protect against the development of
K65R (zidovudine) due to antagonistic mutational interactions.14,15
Viral subtype
Subtypes were defined using the Rega 2 subtyping tool.16,17 Sequences
with an unassigned subtype were excluded from the analysis. The propen-
sity for subtype C to develop K65R appears to be due to polymorphisms at
positions 64 and 65 rather than any other subtype characteristic.18
Subtypes F2, H, CRF07_BC and CRF08_BC19 share the same codon usage as
subtype C at these positions and have been grouped with subtype C for this
analysis. All other subtypes have a B-like codon usage. These were grouped
together, but were not combined with subtype B (creating a non-B/C cat-
egory), as the demographic characteristics of these patients were distinct
from those infected with subtype B virus.
Statistical analysis
Multivariate logistic regression models were fitted to assess the association
between viral subtype and the detection of K65R, adjusting for ART history
as described above. Interaction terms between subtype and current NRTI
exposure were fitted to examine if the effect of subtype on the likelihood of
detection of K65R depended on the specific NRTI being prescribed; subtype
B and subtypes non-B/C were grouped for this analysis. A sensitivity analysis
adjusting for demographic factors (exposure group and ethnicity) in the
main effects model was carried out.
All analyses were performed in STATA version 13.1.
Results
In total, 5100 patients were eligible for analysis, of whom 3410
were infected with a subtype B virus, 810 with a subtype C virus
and 880 with a non-B/C subtype virus. In terms of demographic
characteristics, the subtype C and non-B/C groups were similar,
comprising mainly black heterosexuals, whereas subtype B pa-
tients were predominantly white MSM (Table 1). On average, sub-
type B patients were diagnosed with HIV and started ART several
years earlier than patients infected with other subtypes, and had
higher viral load and CD4 counts prior to ART initiation, presumably
reflecting earlier diagnosis.
Table 2 shows exposure to specific antiretroviral drugs by viral
subtype. Reflecting the earlier date of ART initiation, patients in-
fected with subtype B virus were more likely to have received first-
generation NRTIs (zidovudine, stavudine, didanosine) and less
likely to have received tenofovir. This group also had slightly
greater exposure to PIs and lesser exposure to NNRTIs. Patterns for
the subtype C and subtype non-B/C groups were broadly similar,
except that the latter group had a higher frequency of exposure to
stavudine and to PIs.
Overall, K65R was detected in 446 (8.7%) patients. Note that
this value reflects cumulative incidence (mutation ever detected)
rather than cross-sectional prevalence, and is related to the dur-
ation of drug selection pressure and the number of resistance tests
performed. The frequency of K65R was highest among patients in-
fected with a subtype C virus (14.2%; 115/810), approximately
double that observed for subtype B (7.8%; 267/3410) and subtype
non-B/C (7.3%; 64/880).
The association between K65R detection and viral subtype was
consistently observed regardless of current or previous exposure to
the NRTIs that select for K65R (Figure 1). However, it is not possible
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to draw conclusions about the relative selective pressure exerted
by different NRTIs from this univariate analysis since patients
received many different permutations of the drugs and as K65R
may have been selected on a single occasion or multiple occa-
sions. Among patients who had never taken tenofovir, the drug
that selects most strongly for K65R, the mutation remained com-
monly observed and the subtype difference persisted (Figure 1d).
Table 3 shows the results of the multivariate logistic regression
analysis, which adjusts for individual patient drug exposure. This
analysis confirmed the highly significant difference in the fre-
quency of K65R among subtype C patients compared with subtype
B patients (adjusted OR"2.02, 95% CI" 1.55–2.62, P,0.001).
There was no evidence of a difference between subtype non-B/C
and subtype B viruses (adjusted OR"0.89, 95% CI"0.66–1.21,
P" 0.47). The strongest drug selection pressure was observed for
tenofovir, with patients who were taking this drug at the time of
the resistance test being 5.03-fold (95% CI"3.90–6.50) more
likely to have developed K65R compared with patients who had
never taken tenofovir. Current exposure to abacavir and didano-
sine were also significant predictors of K65R, but no effect of ex-
posure to stavudine (either previous or current) was observed.
As expected, patients taking zidovudine were less likely (adjusted
OR"0.41, 95% CI"0.29–0.59) to develop K65R. Those currently
on an NNRTI were at an increased risk of developing the mutation
(adjusted OR"1.78, 95% CI"1.30–2.44) whereas those currently
on a boosted PI were protected (adjusted OR"0.29, 95%
CI"0.21–0.40). With the exception of tenofovir, previous drug ex-
posure had no effect on the development of K65R, which reflects
the low replicative capacity of this mutation. The sensitivity ana-
lysis, additionally controlling for ethnicity and exposure group,
gave very similar results, but with larger standard errors around
parameter estimates: the adjusted ORs for subtype C and subtype
non-B/C (relative to subtype B) were 2.04 (95% CI"1.35–3.08)
and 0.89 (95% CI"0.57–1.38), respectively (Table 4).
We added interaction effects between subtype and current
NRTI exposure to examine if the subtype C effect was drug de-
pendent. In this analysis subtype B and subtypes non-B/C were
combined to constrain the number of extra parameters. A signifi-
cant association between subtype C and an increased risk of K65R
was observed with tenofovir, abacavir and didanosine. This effect
was not found to be significant amongst those currently on stav-
udine due to a smaller number of K65R mutations occurring
in this group. The OR was lower for tenofovir (OR"1.89,
95% CI"1.18–3.01) than the other NRTIs, although a test for stat-
istical heterogeneity was not significant (P"0.59) (Figure 2).
Discussion
Our analysis provides strong clinical evidence that there is an
increased risk of finding the K65R mutation among subtype
C viruses following virological failure. Our results are in keeping
with previous reports and confirm that patients with subtype C are
twice as likely as those with other subtypes to develop a K65R mu-
tation.8 It is difficult to determine the exact influence subtype has
on the propensity of K65R development in patients with virological
failure due to the fact that subtype C is linked to certain
Table 1. Baseline characteristics by viral subtype
Characteristic
Subtype
Ca (n"810) B (n"3410) non-B/C (n"880)
Year at ART initiation, median (IQR) 2002 (1999–2005) 1997 (1995–2000) 2000 (1997–2004)
Year at HIV diagnosis, median (IQR) 2001 (1997–2004) 1994 (1990–1998) 1999 (1996–2004)
Age at ART initiation (years), median (IQR) 34 (30–40) 34 (29–39) 34 (29–39)
Viral load at ART initiation (copies/mL)b,c, median (IQR) 38900 (2100–204100) 75700 (11000–256200) 51900 (3200–199000)
CD4 count at ART initiation (cells/mm3)b, median (IQR) 134 (46–230) 200 (96–319) 143 (40–232)
Ethnicity, n (%)
white 71 (8.8) 2688 (78.8) 85 (9.7)
black 605 (74.7) 183 (5.4) 647 (73.5)
Asian 20 (2.5) 53 (1.6) 18 (2.0)
other 35 (4.3) 209 (6.1) 24 (2.7)
unknown 79 (9.8) 277 (8.1) 106 (12.0)
Exposure group, n (%)
MSM 39 (4.8) 2650 (77.7) 35 (4.0)
heterosexual-males 241 (29.8) 174 (5.1) 282 (32.0)
heterosexual-females 423 (52.2) 145 (4.3) 444 (50.5)
IVDU 3 (0.4) 170 (5.0) 14 (1.6)
other 30 (3.7) 76 (2.2) 28 (3.2)
unknown 74 (9.1) 195 (5.7) 77 (8.8)
aSubtype C category includes subtypes F2, H, CRF07_BC and CRF08_BC (see the Patients and methods section).
bParameters measured less than 6 months before ART initiation.
cRounded to nearest 100.
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demographic factors such as ethnicity, immigration, culture, life-
style and socioeconomic status. Our study is large enough to con-
trol for this bias because we have a large group of patients with
non-B/C subtypes with similar demographics and baseline charac-
teristics to the patients infected with subtype C viruses in the sense
that this group also consisted largely of black heterosexual pa-
tients (Table 1). It is therefore reasonable to assume that the same
factors that could influence adherence, such as socioeconomic
factors, were broadly the same for the non-B/C and subtype C
groups of patients even though they may have come from differ-
ent countries before residing in the UK. Furthermore, a separate
sensitivity analysis (Table 4) that additionally controlled for ethni-
city and exposure group confirmed the association between sub-
type C and K65R.
Various other factors have also been shown to increase the risk
of K65R development such as current tenofovir and/or NNRTIs,9
dual didanosine! tenofovir therapy,8,20 low starting CD4 count
and length of virological failure.5,21 Zidovudine and/or current
boosted PI-containing therapy is known to reduce the risk.9 As with
other studies, data from this study show that patients infected
with subtype B viruses were more likely to have been exposed to zi-
dovudine, have an earlier calendar year of starting ART (less expos-
ure to tenofovir and more exposure to zidovudine), have higher
CD4 counts and are more likely to be currently on PIs. Looking at
other factors associated with the emergence of K65R, as reported
by von Wyl et al.,9 we also found that current zidovudine or
boosted PI-containing therapy conferred protection (adjusted
OR"0.41 and 0.29, respectively). The risk of K65R developing was
increased on NNRTI-based therapy (adjusted OR"1.78) and the
highest risk was observed with current treatment with tenofovir
(adjusted OR"5.03). Of interest, we also observed that K65R was
common amongst patients who had never been prescribed teno-
fovir (Figure 2).
There is generally a low overall prevalence of K65R reported in
various resistance databases.20,22,23 The Swiss HIV Cohort Study
(SHCS) found a cumulative prevalence of 2.2% amongst patients
on a tenofovir-containing regimen with at least one genotypic re-
sistance test.9 The prevalence is higher when data from patients
who have recently failed ART is analysed and in the aforemen-
tioned study it goes up to 10.1% in patients on tenofovir. Data ana-
lysis from the UK CHIC Study, which is a representative cohort of
the UK HIV population on ART, shows the prevalence of K65R to be
13.2% in those failing a tenofovir- and efavirenz-based regimen.21
There is a further increase in K65R prevalence in developing coun-
tries in patients who fail a non-zidovudine-containing NRTI regi-
men. This is especially the case in sub-Saharan Africa where
subtype C viruses predominate.24–27 A recent multicentre retro-
spective cohort study (TenoRes) that combined data from cohorts
and clinical trials across 36 countries found K65R prevalence rates
of more than 50% in sub-Saharan African patients with treatment
failure on tenofovir- and NNRTI-based regimens.5 The wide vari-
ation in the worldwide prevalence of K65R is most likely explained
by different standards of care, most notably the length of time
spent on failing ART, but our data indicate that subtype C per se
contributes to the high prevalence seen in countries where subtype
C is prevalent. The OR of 1.95 we observed is roughly in keeping
with the ORs observed in the TenoRes cohort study5 (OR"2.44)
and the EuResist consortium study (OR"2.22),8 which confirms
that subtype C is significantly associated with a higher probability
of K65R emergence.
Our data are consistent with previous evidence that subtype C
is a strong risk factor for the development of K65R in patients with
virological failure. The clinical implication may therefore be that
patients who are infected with subtype C viruses are at an
increased risk of virological failure because of the propensity of the
virus to develop a K65R mutation when on a tenofovir-based regi-
men. This seems to be supported by two recent studies.28,29
However, when we studied this hypothesis using UK CHIC data, we
found that although subtype C and subtype non-B/C viruses have
virological failure rates twice as high as patients with subtype
B viruses, the difference disappeared when adjusted for demo-
graphic and clinical characterises.30 An explanation for the differ-
ences in treatment response and risk of K65R developing between
subtypes could be that a single point mutation under an optimal
treatment setting does not affect outcome. However, when other
factors that lead to differential non-adherence, such as
Table 2. ART exposure by viral subtype
ART exposure
Subtype
C (n"810),
n (%)
B (n"3410),
n (%)
non-B/C (n"880),
n (%)
TDF
previous 75 (9.3) 271 (7.9) 97 (11.0)
current 309 (38.1) 1032 (30.3) 339 (38.5)
ever 384 (47.4) 1303 (38.2) 436 (49.5)
ABC
previous 118 (14.6) 481 (14.1) 145 (16.5)
current 210 (25.9) 797 (23.4) 220 (25.0)
ever 328 (40.5) 1278 (37.5) 365 (41.5)
ddI
previous 155 (19.1) 1015 (29.8) 216 (24.5)
current 113 (14.0) 886 (26.0) 161 (18.3)
ever 268 (33.1) 1901 (55.7) 377 (42.8)
d4T
previous 180 (22.2) 1224 (35.9) 240 (27.3)
current 61 (7.5) 854 (25.0) 106 (12.0)
ever 241 (29.8) 2078 (60.9) 346 (39.3)
ZDV
previous 302 (37.3) 1687 (49.5) 393 (44.7)
current 233 (28.8) 830 (24.3) 213 (24.2)
ever 535 (66.0) 2517 (73.8) 606 (68.9)
PI
previous 126 (15.6) 837 (24.5) 163 (18.5)
current 298 (36.8) 1421 (41.7) 393 (44.7)
ever 424 (52.3) 2258 (66.2) 556 (63.2)
NNRTI
previous 247 (30.5) 1019 (29.9) 304 (34.5)
current 352 (43.5) 1247 (36.6) 339 (38.5)
ever 599 (74.0) 2266 (66.5) 643 (73.1)
TDF, tenofovir disoproxil fumarate; ABC, abacavir; ddI, didanosine; d4T,
stavudine; ZDV, zidovudine.
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demographics and clinical characteristics, are present then sub-
type C viruses have a greater propensity to develop a K65R
mutation.31
Small retrospective retreatment cohort studies suggested that
second-line therapy is as successful with K65R as when the muta-
tion is not present, usually with zidovudine in the regimen. The
strongest predictor of virological response was the addition of zi-
dovudine to the retreatment regimen.32 However, the high preva-
lence of K65R in low-income countries where K65R presence can
be as high as 50% has led to increasing use of zidovudine in
second-line therapy. Further second-line studies are needed in
order to establish if and when it is safe to remove zidovudine and
possibly re-use tenofovir! lamivudine/emtricitabine when the
viral load has become fully suppressed and the individual is on a
boosted PI.
A further implication of this study is that pre-exposure
prophylaxis (PrEP) could potentially be compromised in coun-
tries where subtype C viruses are common. So far, PrEP studies
using tenofovir+ emtricitabine have reported a low incidence
of K65R acquisition when failing tenofovir-based PrEP, even
when more sensitive sequencing is employed.33 The influence
of subtype C on the likelihood of K65R development has not yet
been studied in patients with PrEP failure due to the low inci-
dence of breakthrough infections and resistance in clinical trial
settings. Our data would suggest a possible increased risk of
acquiring K65R in patients with subtype C virus who fail PrEP, es-
pecially in settings where PrEP is not stopped soon after sero-
conversion. K65R resistance also tends to disappear within a
month of stopping ART34 and therefore more sensitive baseline
resistance testing may need to be performed in patients with a
history of PrEP usage without adequate monitoring. The role of
emtricitabine/lamivudine in dual-therapy PrEP might also miti-
gate against the risk of early resistance to tenofovir. It still has
to be established if minority variant K65R substantially increases
a patient’s risk of virological failure in a resource-limited
setting.35
A strength of this study is the study size, which makes it the
largest comparative study to date, with more patients than
the EuResist consortium study.8 A shortcoming of many studies is
the strong association between viral subtype, exposure groups and
ethnicity, which are difficult to differentiate. The subtype diversity
of the epidemic in the UK made it possible to compare subtype C
viruses with non-B/C subtype viruses that share similar demo-
graphics and treatment history, but which have different viral
templates.
This study included patients with a number of different NRTI ex-
posure histories, which included some of the older NRTIs, which
could be considered a weakness of the study. However, this would
not have unduly influenced the results as this study mainly
explored the hypothesis that the subtype C template has a predi-
lection for developing a K65R mutation. A further consideration is
the fact that the K65R mutation could have disappeared due to
the adverse effect it has on replication fitness of the virus upon
stopping combination ART and could therefore be underrepre-
sented in our database. It is also possible that K65R existed as a
minority variant prior to therapy as a result of undetected trans-
mitted drug resistance, but the possibility of this is small and
should not have affected our results.
In conclusion, our analysis shows that patients with subtype C
HIV-1 have approximately double the frequency of K65R in our
database compared with other subtypes. The exact clinical impli-
cations of this finding need to be further elucidated.
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never 2554 202 (7.9) 1.00 1.00 —
past 1386 79 (5.7) 0.70 0.97 0.69–1.37
current 1160 165 (14.2) 1.93 2.66 2.00–3.53
d4T exposure 0.81
never 2435 229 (9.4) 1.00 1.00 —
past 1644 153 (9.3) 0.99 0.93 0.69–1.25
current 1021 64 (6.3) 0.64 0.89 0.61–1.29
ZDV exposure ,0.001
never 1442 187 (13.0) 1.00 1.00 —
past 2382 208 (8.7) 0.64 0.80 0.62–1.04
current 1276 51 (4.0) 0.28 0.41 0.29–0.59
PI exposure ,0.001
never 1862 224 (12.0) 1.00 1.00 —
past 1126 128 (11.4) 0.94 0.84 0.63–1.11
current 2112 94 (4.5) 0.34 0.29 0.21–0.40
NNRTI exposure ,0.001
never 1592 68 (4.3) 1.00 1.00 —
past 1570 109 (6.9) 1.67 1.12 0.79–1.59
current 1938 269 (13.9) 3.61 1.78 1.30–2.44
TDF, tenofovir disoproxil fumarate; ABC, abacavir; ddI, didanosine; d4T,
stavudine; ZDV, zidovudine.
aAdjusted OR from main effects model.
Table 4. Logistic regression analysis of detection of K65R by viral sub-
type and demographic factors
Total K65R, n (%) OR aORa 95% CI P
Subtype ,0.001
B 3410 267 (7.8) 1.00 1.00 —
C 810 115 (14.2) 1.95 2.04 1.35–3.08 0.001
non-B/C 880 64 (7.3) 0.92 0.89 0.57–1.38 0.60
Ethnicityb 0.35
white 2844 217 (7.6) 1.00 1.00 —
black 1435 153 (10.7) 1.44 1.28 0.88–1.85
Asian 91 5 (5.5) 0.70 0.69 0.27–1.80
other 268 18 (6.7) 0.87 0.85 0.50–1.45
Exposureb 0.12
MSM 2724 222 (8.1) 1.00 1.00 —
heterosexual-males 697 75 (10.8) 1.36 1.00 0.66–1.52
heterosexual-females 1012 92 (9.1) 1.13 0.68 0.45–1.04
IVDU 187 15 (8.0) 0.98 1.05 0.58–1.90
other 134 8 (6.0) 0.72 0.53 0.24–1.17
aAdjusted OR from main effects model, adjusting for drug exposure and
other factors in table.
bUnknown categories included in model, but excluded from table and
calculation of P.
Current d4T
Current ddI
Current ABC
Current TDF
Overall
0.5 1 2 4 8
OR (subtype C versus non-C subtypes)
Figure 2. Likelihood of K65R mutation in subtype C viruses versus all
other subtypes by current NRTI exposure. Estimates derived from ex-
tended logistic regression model including interaction terms. TDF, teno-
fovir disoproxil fumarate; ABC, abacavir; ddI, didanosine; d4T, stavudine.
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